Author | Michael J. Morris, MD

Articles

The Rationale of the TAX 3503 Trial in Prostate Cancer

August 05, 2014

Michael J. Morris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, explains the rationale behind TAX 3503 (hormonal therapy +/- docetaxel for patients at high risk of metastatic prostate cancer).